Novartis: 3-Billion-USD Acquisition Secures Potential Blockbuster in Breast Cancer Therapy!
Reading Time: 4 minutes
The Swiss pharmaceutical company Novartis is investing up to 3 billion USD in the acquisition of the Synnovation subsidiary Pikavation Therapeutics, thereby securing the rights to the breast cancer drug candidate SNV4818. With this acquisition in the USA, the company is enhancing its oncology portfolio with a targeted therapy currently in clinical phases 1/2. The aim is to establish new, patent-protected revenue streams in the core segment of cancer therapies by addressing a specific gene mutation in HR+/HER2-negative breast cancer in the medium...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
